Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Bodur H, Ataman S, Rezvani A, Buğdaycı DS, Cevik R, Birtane M, Akıncı A, Altay Z, Günaydın R, Yener M, Koçyiğit H, Duruöz T, Yazgan P, Cakar E, Aydın G, Hepgüler S, Altan L, Kırnap M, Olmez N, Soydemir R, Kozanoğlu E, Bal A, Sivrioğlu K, Karkucak M, Günendi Z. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011;20:543-9. [PMID: 20978859 DOI: 10.1007/s11136-010-9771-9] [Citation(s) in RCA: 94] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/04/2010] [Indexed: 01/22/2023]

For:	Bodur H, Ataman S, Rezvani A, Buğdaycı DS, Cevik R, Birtane M, Akıncı A, Altay Z, Günaydın R, Yener M, Koçyiğit H, Duruöz T, Yazgan P, Cakar E, Aydın G, Hepgüler S, Altan L, Kırnap M, Olmez N, Soydemir R, Kozanoğlu E, Bal A, Sivrioğlu K, Karkucak M, Günendi Z. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011;20:543-9. [PMID: 20978859 DOI: 10.1007/s11136-010-9771-9] [Citation(s) in RCA: 94] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/04/2010] [Indexed: 01/22/2023]

Number

Cited by Other Article(s)

Drouet J, López-Medina C, Molto A, Granger B, Fautrel B, Gaujoux-Viala C, Kiltz U, Dougados M, Gossec L. Global health in axial spondyloarthritis: thresholds for the Assessment of SpondyloArthritis international Society Health Index and the EuroQol score: analysis of the ASAS-PerSpA study. Scand J Rheumatol 2025;54:175-183. [PMID: 39679471 DOI: 10.1080/03009742.2024.2424085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Accepted: 10/29/2024] [Indexed: 12/17/2024]

Abstract

OBJECTIVES

In axial spondyloarthritis (axSpA), patient-perceived quality of life/global functioning and health (GH) can be assessed using disease-specific [Assessment of SpondyloArthrit is international Society Health Index (ASAS-HI)] or generic [(3-level EuroQol 5 Dimensions (EQ-5D-3L)] scores. Our objectives were to explore the link between these scores and to define thresholds for good and poor GH.

METHOD

We conducted a post-hoc analysis of the cross-sectional ASAS-PerSpA study for patients fulfilling ASAS criteria for axSpA. The ASAS-HI and EQ-5D scores were analysed visually (distribution, scatterplot) and through Spearman correlation and agreement (deciles). To determine cut-offs for good and poor GH on EQ-5D based on the validated ≤5 and ≥12 cut-offs for ASAS-HI, respectively, receiver operating characteristics (ROC) curves and distribution-based methods were applied. Validity was assessed using crude concordance and prevalence-adjusted bias-adjusted kappa; discordance between groups was explored.

RESULTS

In 2651 patients (median age 41.0 years, 66.5% men), the correlation between ASAS-HI and EQ-5D was high (r = -0.73) and agreement (between deciles) was moderate (weighted kappa = 0.51). Both ROC areas under the curve were 0.86; thresholds of 0.69 and 0.54 for EQ-5D were chosen for good and poor GH, respectively. Crude concordances and agreement were satisfactory (0.80-0.81 and 0.60-0.61, respectively). The EQ-5D cut-off for good GH performed better than that for poor GH.

CONCLUSION

ASAS-HI and EQ-5D were highly correlated but did not fully overlap. We propose EQ-5D thresholds corresponding to the ASAS-HI thresholds for good and poor GH; however, caution is needed when assessing poor GH with EQ-5D. These findings will be useful to compare GH when only one of the outcome measures is available.

Collapse

Lobo-Prat D, Sainz L, Laiz A, De Dios A, Fontcuberta L, Fernández S, Masip M, Riera P, Pagès-Puigdemont N, Ros S, Gomis-Pastor M, Corominas H. Designing an integrated care pathway for spondyloarthritis: A Lean Thinking approach. J Eval Clin Pract 2025;31:e14132. [PMID: 39253893 DOI: 10.1111/jep.14132] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2024] [Revised: 08/07/2024] [Accepted: 08/16/2024] [Indexed: 09/11/2024]

Abstract

INTRODUCTION

Integrated care pathways (ICPs) are crucial for delivering individualised care. However, the development of ICPs is challenging and must be well designed to provide the expected benefits. Regarding this, healthcare organisations are increasingly adopting management systems based on Lean Thinking to improve their organisational processes by eliminating non-value-added steps. This study elucidates the process and evaluates the impact of applying Lean Thinking to redesign an ICP for patients with spondyloarthritis, a chronic inflammatory disease affecting young adults.

METHODS

A multidisciplinary team was assembled and trained in Lean Thinking. Patient's perspective was gathered through a focus group. Guided by an expert methodologist, the team constructed a value stream map of the entire care pathway and analysed each step. Five work streams were defined to increase value at each step, leading to targeted process improvements. Key process and outcome metrics were collected and compared in 2-month baseline and post-implementation audits.

RESULTS

A total of 118 patients were included in the baseline audit (September-October 2022), and 116 in the post-implementation audit (January-February 2023). Process redesign resulted in statistically significant improvements (p < 0.05), including a reduction in the mean number of hospital visits per patient over a 2-month period from 2.54 (SD = 0.93) to 1.84 (SD = 0.79), an increase in complementary exams scheduled on the same day (81.4% to 94.8%) and an increase in baseline disease and treatment education (from 22.2% to 84.2% and from 18.2% to 84.6%, respectively). Regarding standardisation of clinical practice, there were significant increases in collecting data for medical records on composite activity indices (76.3% to 95.7%), reporting of pharmacological treatment adherence (68.6% to 94%) and providing nonpharmacological recommendations (31.3% to 95.7%).

CONCLUSIONS

The application of Lean Thinking to redesign the spondyloarthritis ICP led to significant improvements in outpatient appointment scheduling, reduced patient hospital visits, improved interdepartmental coordination and standardised clinical practice.

Collapse

Affiliation(s)

David Lobo-Prat Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Rheumatology Department, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain Faculty of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Luis Sainz Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Faculty of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Ana Laiz Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Faculty of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Anna De Dios Faculty of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain Digital Health Validation Center, Digital Health Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Lalis Fontcuberta Lean Management Institute, Barcelona, Spain
Susana Fernández Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Montserrat Masip Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Pau Riera Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
Neus Pagès-Puigdemont Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Sandra Ros Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Mar Gomis-Pastor Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain Digital Health Validation Center, Digital Health Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hèctor Corominas Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Faculty of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain

Collapse

Gündüz Gül YÖ, Bal A, Erdem ÜG. Is there an anti-inflammatory effect of aerobic exercises on axial spondyloarthropathy patients? A prospective, randomized-controlled trial. Arch Rheumatol 2025;40:98-111. [PMID: 40264476 PMCID: PMC12010269 DOI: 10.46497/archrheumatol.2025.10924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2024] [Accepted: 01/14/2025] [Indexed: 04/24/2025] Open

Abstract

Objectives

This study aims to examine whether aerobic exercises, in addition to home-based exercise (HBE) program, had anti-inflammatory effects, evaluated by disease activity, acute phase reactants, and cytokine levels in axial spondyloarthropathy (axSpA).

Patients and methods

This two parallel-group, unblinded, 12-week, prospective, randomized-controlled trial (RCT) included a total of 54 participants who were followed for axSpa and the patients were equally allocated to the aerobic exercise group or HBE group. The aerobic exercise group included 27 patients (8 males, 19 females, mean age: 43.9±9.0 years; range, 27 to 58 years) and the HBE group included 27 patients (8 males, 19 females, mean age: 42.4±10.5 years; range, 23 to 63 years). The patients were evaluated using the Ankylosing Spondylitis Disease Activity Score (ASDAS), Visual Analog Scale (VAS), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), chest expansion measurement, 6-Min Walk Test, and Ankylosing Spondylitis Quality of Life (ASQoL), Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tumor necrosis factoralpha (TNF-α) and interleukin-17 (IL-17) levels at the beginning of the study and after treatment completion. The HBE group was provided conventional exercise program. The second group ran on the treadmill in addition to their HBE program. Exercise sessions were performed three times a week for a period of 12 weeks.

Results

After treatment, only the aerobic exercise group showed a significant improvement in disease activity (p<0.001). Both HBE and aerobic exercise groups showed a significant improvement in pain levels, functional statement, spinal mobility, chest expansion, functional exercise capacity, and life quality (p<0.001, p<0.001; p<0.001, p<0.001; p=0.03, p<0.001; p=0.008, p<0.001; p=0.004, p<0.001; p<0.001, and p<0.001, respectively). Only the HBE group showed a significant decrease in TNF-α levels and ESR (p=0.015, p=0.014). After treatment, the aerobic exercise group showed more improvement in disease activity, pain levels, functional exercise capacity, and quality of life compared to the HBE group (p<0.001, p=0.005, p<0.001, p=0.038). The change in post-treatment ESR, CRP, TNF-α, and IL-17 levels compared to pre-treatment did not show a statistically significant difference between the HBE and aerobic exercise groups (p>0.05).

Conclusion

Adding aerobic exercise to a conventional exercise program may have an anti-inflammatory effect by reducing disease activity and help to manage disease.

Collapse

Zlatkovic-Svenda M, Djokic A, Perunicic A, Zdravkovic M, Dolijanovic SP, Thorpe J, Dudok D, Milicevic J, Petrovic D, Radunovic G. Translation, cross-cultural adaptation and psychometric evaluation of the Serbian Ankylosing Spondylitis Quality of Life (ASQoL) Questionnaire (refers to r-axSpA) and its relations with disease activity and functional status indices. J Patient Rep Outcomes 2025;9:8. [PMID: 39812921 PMCID: PMC11735697 DOI: 10.1186/s41687-025-00838-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2024] [Accepted: 01/06/2025] [Indexed: 01/16/2025] Open

Abstract

OBJECTIVES

To translate, cross-culturally adapt and validate the Serbian Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire, e.g. according to the new nomenclature Radiographic-Axial Spondyloarthritis (r-axSpA), and to relate it to disease activity and functional status domains.

METHODS

Four stages were accomplished: (1) Bilingual and lay panel for translation and cross-cultural adaptation (2) Cognitive debriefing interviews (assessing the language and cultural equivalence of the concepts used in the Serbian ASQoL translation) for face and content validity (3) Psychometric evaluation: (a) convergent validity by NHP as a comparator scale and (b) known group validity by correlations with disease activity and overall health status and reliability (internal consistency and test-retest reliability) (4) Independent regression analyses for relations between ASQoL and ASDAS, BASDAI, BASFI, Schober's test, respiratory index and SPARCC were used. The statistical program SPSS (version 21; IBM, Armonk, NY, USA) was used.

RESULTS

The bilingual panel made a unified version of the translated documents, a lay panel confirmed the clarity of the questionnaire. Cognitive debriefing interviews with 10 patients evaluated the Serbian ASQoL as clear, precise, easy to complete. The psychometric properties with 60 randomly selected patients showed good convergent validity between ASQoL and NHP domains of pain (r = 0.79), emotional reactions (r = 0.78), physical activity (r = 0.77) and energy (r = 0.75). The internal reliability was 0.95 and 0.91 (1st and 2nd administration), respectively, and the test-retest reliability was 0.84. Regression analyses showed highly significant relationships (p < 0.001) between ASQoL and ASDAS (R²=0.403), BASDAI (R²=0.564) and BASFI (R²=0.444).

CONCLUSION

The Serbian ASQoL demonstrated good psychometric properties and significant relationships with disease activity and functional status and is recommended for quality of life assessment in Serbian-speaking ankylosing spondylitis (radiographic axial spondyloarthritis) patients, both in clinical practice and clinical research.

Collapse

Qu X, Xu X, Jiang Q, Chen Y, Geng Z, Yang K, Yu Q, Sun T, Liu H. Clinical performance of the ASAS health index in chinese patients with ankylosing spondylitis and its influencing factors. Clin Rheumatol 2024;43:2541-2550. [PMID: 38976092 DOI: 10.1007/s10067-024-07045-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 04/23/2024] [Accepted: 05/12/2024] [Indexed: 07/09/2024]

Abstract

OBJECTIVE

The aim of this study was to investigate the status of health-related quality of life in Chinese patients with ankylosing spondylitis (AS) and to analyze factors associated with the Assessment of SpondyloArthritis international Society Health Index (ASAS-HI) in AS and its relationship with disease activity and psychological status.

METHODS

A cross-sectional study of 484 patients with AS attending 10 hospitals in China from March 2021 to September 2023 was recruited. The ASAS-HI assessed general health and functional status; the Depression Anxiety Stress Scales (DASS-21) assessed psychological disorders such as anxiety, depression, and stress; and the Functional Assessment of Chronic illness Therapy-Fatigue Scale (FACIT-F) assessed patients' fatigue symptoms; the Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Bath Ankylosing Spondylitis Measurement Index (BASMI) were used to assess patients' disease activity and functional impairment. The correlation between ASAS-HI and the ASDAS, poor psychological status, and fatigue symptoms was observed. Univariate and multivariate logistic regression analyses were used to explore the relevant influencing factors of ASAS-HI.

RESULTS

A total of 484 patients were included in this study of whom 162 were in poor health, 139 in moderate health, and 183 in good health. On univariate analysis, disease activity is an important factor affecting ASAS-HI. People with extremely high disease activity (ASDAS ≥ 3.5) had a 12 times elevated risk of having poor health status (OR = 12.53; P < 0.001). Other significant covariates included age ≥ 36 (OR = 1.58; P = 0.015), BMI ≥ 24 kg/m2 (OR = 2.93; P = 0.013), smoke (OR = 1.96; P = 0.002), BASFI (OR = 1.49; P < 0.001), BASMI (OR = 1.22; P < 0.001), fatigue (OR = 6.28; P < 0.001), and bad psychological conditions such as depression (OR = 10.86; P < 0.001), anxiety (OR = 3.88; P < 0.001), and stress (OR = 4.65; P < 0.001). The use of bMARDs is inversely associated with the appearance of adverse health status (OR = 0.54; P = 0.012). There was no significant relationship between HLA-B27 and sex. Multivariable logistic regression showed that higher disease activity (ASDAS ≥ 3.5) (OR = 5.14; P = 0.005), higher scores of BASMI (OR = 1.10; P = 0.009), self-reported depression (OR = 3.68; P = 0.007), and fatigue (OR = 2.76; P < 0.001) were factors associated with adverse health status.

CONCLUSION

The health status of AS patients is related to age, BMI, smoking, disease activity, poor psychological status, and fatigue and is influenced by a combination of multiple factors such as emotional state, economic level, pain, and dysfunction. Therefore, clinicians should pay attention to the early assessment of ASAS-HI in order to improve the prognosis of the disease. Key Points •Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease with a long course and heavy disease burden, which greatly affects patients' quality of life. Therefore, this study aims to evaluate the health status of ankylosing spondylitis in the Chinese population and its influencing factors. •This is a multi-center cross-sectional study in China, which can better reflect the overall situation of the Chinese population.

Collapse

de Vlam K, Maksymowych WP, Gallo G, Rahman P, Mease P, Krishnan V, McVeigh CJ, Lisse J, Zhu D, Bolce RJ, Conaghan PG. Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial. Rheumatol Ther 2024;11:691-707. [PMID: 38637464 PMCID: PMC11111437 DOI: 10.1007/s40744-024-00660-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Accepted: 02/27/2024] [Indexed: 04/20/2024] Open

Abstract

INTRODUCTION

The objective of this analysis is to evaluate the improvement in spinal pain with ixekizumab, placebo, and adalimumab based on objective measures of inflammation response in patients with ankylosing spondylitis (AS).

METHODS

The COAST-V 52-week, double-blind, placebo-controlled, randomized phase III trial examined the efficacy of ixekizumab in patients with active AS; adalimumab was used as an active reference arm. Treatment effects on reduction in pain were assessed by objective measures of controlled and persisting inflammation (defined by magnetic resonance imaging [MRI], C-reactive protein [CRP], or MRI + CRP status). Pathway analysis was used to analyze treatment effect that was not attributable to reduction in inflammation biomarkers.

RESULTS

In patients with AS, when inflammation was controlled as assessed by MRI, patients treated with ixekizumab experienced a reduction in spinal pain at night (SP-N, numeric rating scale, ixekizumab mean = - 3.9, p < 0.001, adalimumab mean = - 2.6, p < 0.05) compared to placebo (mean = - 1.6) at week 16. When inflammation was controlled as assessed by MRI + CRP, ixekizumab and adalimumab had numerically greater reductions at week 16 in SP-N versus placebo. All ixekizumab groups had further improvements at week 52. When inflammation was persisting as assessed by MRI + CRP, ixekizumab-treated patients had significant reduction in SP-N (mean = - 3.7, p < 0.001) versus placebo (mean = - 1.7), improvement with adalimumab did not reach significance (mean = - 2.6, p = 0.06). In the pathway analysis at week 16, ixekizumab had a greater effect on pain outcomes compared to adalimumab.

CONCLUSION

This post hoc analysis is supportive of the hypothesis that ixekizumab reduces pain in AS by additional mechanisms other than the reduction of measurable inflammation.

TRIAL REGISTRATION NUMBER

NCT02696785.

Collapse

Kaçan H, Kaş Alay G, Yildiz E. The effect of education given to Turkish adolescents with Familial Mediterranean fever on anxiety, depression, and quality of life. Eur J Pediatr 2023:10.1007/s00431-023-04975-5. [PMID: 37069356 DOI: 10.1007/s00431-023-04975-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 04/04/2023] [Accepted: 04/06/2023] [Indexed: 04/19/2023]

Abstract

To examine the effects of individual education given to Turkish adolescents with Familial Mediterranean fever (FMF) on anxiety, depression, and quality of life. The randomized controlled experimental study was performed on 70 adolescents aged 12-18 years who were diagnosed as having FMF between October 2021 and April 2022 in Turkey. The disease management education was offered individually to adolescents in the intervention group with a booklet entitled "FMF is under my control;" no intervention was applied to adolescents in the control group. The training booklet was prepared by the researchers in a multidisciplinary team and was finalized by taking expert opinions. In the data collection process, a personal information form, the State-Trait Anxiety Inventory for Children (STAI-CH), the children's depression inventory (CDI), and the Pediatric Quality of Life Inventory (PedsQL) were used. After applying the scales specified in the pretest, individual training was given and the posttest was performed 2 months later using the same scales. After the education, there was a statistically significant decrease in the mean CDI score of the intervention group (p < 0.05), whereas there were statistically significant increases in mean scores obtained on PedsQL and its sub-scales (p < 0.05). However, the decrease in the mean STAI-CH score of the intervention group was not statistically significant (p > 0.05). There was no statistically significant difference in the mean STAI-CH, CDI, and PedsQL scores of the control group after the education (p > 0.05). Conclusion: The effectiveness of the individual education program for adolescents with FMF in improving quality of life and reducing levels of depression within the scope of disease management has been confirmed. It is recommended that all health professionals working with children with FMF regularly provide individual or group-planned education programs. What is Known: • The unpredictability of FMF attacks has a very negative effect on adolescents. • Individual education programs on FMF focus on children with a holistic approach. What is New: • To the best of our knowledge, this study is the first study to evaluate disease management education given to adolescents with FMF. • This is a pioneering study of the use of nurses in the education of adolescents with FMF and in fulfilling their educational roles.

Collapse

Öztürk Ö, Feyzioğlu Ö, Sarıtaş F. Identifying frailty and its associated factors in patients with axial spondyloarthritis. Int J Rheum Dis 2023;26:519-530. [PMID: 36737413 DOI: 10.1111/1756-185x.14591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Revised: 12/16/2022] [Accepted: 01/16/2023] [Indexed: 02/05/2023]

Bergman MJ, Zueger P, Patel J, Saffore CD, Topuria I, Cavanaugh C, Fang S, Clewell J, Ogdie A. Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry. Rheumatol Ther 2023;10:187-199. [PMID: 36333490 PMCID: PMC9931970 DOI: 10.1007/s40744-022-00504-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Accepted: 10/13/2022] [Indexed: 11/06/2022] Open

Abstract

BACKGROUND

There is limited evidence on the clinical and economic benefit of achieving disease control in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), thus we aimed to assess the impact of disease control on healthcare resource use (HCRU) and direct medical costs among US patients with PsA or AS over 1 year.

METHODS

Data were derived from the US OM1 PsA/AS registries (PsA: 1/2013-12/2020; AS: 01/2013-4/2021) and the Optum Insight Clinformatics® Data Mart to identify adult patients with PsA or AS. Two cohorts were created: with disease control and without disease control. Disease control was defined as modified Disease Activity Index for Psoriatic Arthritis (DAPSA28) ≤ 4 for PsA and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) < 4 for AS. Outcomes were all-cause inpatient, outpatient, and emergency department (ED) visits and associated costs over a 1-year follow-up period. Mean costs per person per year (PPPY) were assessed descriptively and adjusted odds ratios (aOR) with 95% confidence intervals (CI) were estimated for the likelihood of HCRU by logistic regression.

RESULTS

The study included 1235 PsA (with disease control: N = 217; without: N = 1018) and 581 AS patients (with disease control: N = 342; without: N = 239). Patients without disease control were more likely to have an inpatient (aOR [95% CI]; PsA: 3.0 [0.9, 10.1]; AS: 7.7 [2.3, 25.1]) or ED (PsA: 1.6 [0.6, 4.2]; AS: 3.5 [1.5, 8.3]) visit than those with disease control. Those without disease control, vs. those with disease control, had greater PPPY costs associated with inpatient (PsA: $1550 vs. $443), outpatient (PsA: $1789 vs. $1327; AS: $2498 vs. $2023), and ED (PsA: $114 vs. $57; AS: $316 vs. $50) visits.

CONCLUSIONS

Findings from this study demonstrate lower disease activity among patients with PsA and AS is associated with less HCRU and lower costs over the following year.

Collapse

van der Zee-Neuen A, Strobl V, Dobias H, Fuchs J, Untner J, Foisner W, Knapp M, Edtinger S, Offenbächer M, Ritter M, Hölzl B, Gaisberger M. Sustained improvements in EQ-5D utility scores and self-rated health status in patients with ankylosing spondylitis after spa treatment including low-dose radon - an analysis of prospective radon indication registry data. BMC Musculoskelet Disord 2022;23:743. [PMID: 35922780 PMCID: PMC9347130 DOI: 10.1186/s12891-022-05691-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 07/20/2022] [Indexed: 12/02/2022] Open

Affiliation(s)

Antje van der Zee-Neuen Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology, Salzburg, Austria. .,Gastein Research Institute, Paracelsus Medical University, Strubergasse 22, 5020, Salzburg, Austria. .,Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria. .,Center for Public Health and Healthcare Research, Paracelsus Medical University, Salzburg, Austria.
Victoria Strobl Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology, Salzburg, Austria.,Gastein Research Institute, Paracelsus Medical University, Strubergasse 22, 5020, Salzburg, Austria.,Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Salzburg, Austria
Heidemarie Dobias Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology, Salzburg, Austria.,Gastein Research Institute, Paracelsus Medical University, Strubergasse 22, 5020, Salzburg, Austria.,Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Salzburg, Austria
Julia Fuchs Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology, Salzburg, Austria.,Gastein Research Institute, Paracelsus Medical University, Strubergasse 22, 5020, Salzburg, Austria.,Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Salzburg, Austria
Johannes Untner Gastein Healing Gallery, Bad Gastein, Austria
Wolfgang Foisner Cure and Rehabilitation Center, Bad Hofgastein, Austria
Martina Knapp Stiftung Kurtherme Badehospiz, Bad Gastein, Austria
Sebastian Edtinger Baerenhof Health Care & Rehabilitation Center, Bad Gastein, Austria.,Department of Physical Medicine and Rehabilitation, Kardinal Schwarzenberg Klinikum, Schwarzach Im Pongau, Austria
Martin Offenbächer Gastein Healing Gallery, Bad Gastein, Austria
Markus Ritter Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology, Salzburg, Austria.,Gastein Research Institute, Paracelsus Medical University, Strubergasse 22, 5020, Salzburg, Austria.,Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Salzburg, Austria.,Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology, Pathophysiology and Biophysics, Nuremberg, Germany.,Kathmandu University School of Medical Sciences, Dhulikhel, Nepal
Bertram Hölzl Gastein Healing Gallery, Bad Gastein, Austria.,Department of Internal Medicine, Landesklinik St. Veit Im Pongau, SALK, Paracelsus Medical University, Salzburg, Austria
Martin Gaisberger Center for Physiology, Pathophysiology and Biophysics, Institute for Physiology and Pathophysiology, Salzburg, Austria. .,Gastein Research Institute, Paracelsus Medical University, Strubergasse 22, 5020, Salzburg, Austria. .,Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Salzburg, Austria.

Collapse

Association of fear assessment in inflammatory rheumatic diseases (FAIR) questionnaire with ankylosing spondylitis quality of life and disease activity in patients with ankylosing spondylitis. JOURNAL OF SURGERY AND MEDICINE 2022. [DOI: 10.28982/josam.1119839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open

Abstract Background/Aim: Fear against disease course, treatment, and limitations in family, work, and social life are commonly seen but mostly overlooked by physicians of patients with chronic inflammatory rheumatic diseases. Ankylosing spondylitis (AS) is a chronic inflammatory disease in young adults characterized by limitations in spinal mobility. The Fear Assessment (FAIR) Questionnaire was designed especially for patients with rheumatoid arthritis and spondyloarthritis to assess the level of fear from the patient’s perspective. Here we evaluate the FAIR score in AS patients and its association with disease activity, AS quality of life (ASQoL), depression, anxiety, and fatigue levels. Methods: This cross-sectional study included 79 patients with AS, and disease activity was assessed by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), AS-Disease Activity Score-C reactive protein, and functional status was assessed by Bath Ankylosing Spondylitis Functional Index (BASFI). Patient global assessment of disease and pain were scored on 0–10 cm visual analog scores. All patients completed FAIR and ASQoL questionnaires. The depression and anxiety were evaluated by Hospital Anxiety and Depression Scale (HADS), and fatigue was assessed by Fatigue Severity Scale (FSS). Results: The mean age of AS patients (62% male) was 41.7 (11.3) years. Most of the patients were on biological disease-modifying anti-rheumatic drugs (bDMARDs). The patients’ median BASDAI, ASDAS-CRP, and BASFI were 5.4 (range, 3.8–7.4), 3.83 (1.4), and 4.0 (range, 2.3–6.2), respectively. The overall FAIR, ASQoL, FSS, HADS-depression, and HADS-anxiety scores were 75 (range, 52–91), 9.6 (5.2), 5.4 (range, 4.1–7), 7.7 (4.4) and 9.6 (5.2), respectively. There were statistically significant correlations between disease activity indices and FAIR, ASQoL, FSS, and HADS scores. The FAIR scores significantly correlated with ASQoL, FSS, and HADS scores. The patients with active disease (BASDAI ≥ 4) had significantly higher levels of FAIR, ASQoL, FSS, and HADS. The best cut-off value for the FAIR score of AS patients with moderate to severe disease activity was 50 (AUC: 0.734, 95% CI [0.599–0.870], P = 0.002), with a sensitivity of 89.8%, specificity of 55%, positive likelihood ratio of 1.99, and Youden index of 0.45. Conclusion: This study shows that AS patients face a high level of fear which is associated with higher disease activity, higher risk of mood disorders, and lower quality of life. Physicians should not only focus on the physical improvement of the patient but also handle the fear of patients against their diseases and their treatment. This holistic approach will improve the dialogue between the physician and the patient, which will result in increased compliance with treatment and will raise the quality of care. Collapse

Athanassiou P, Kotrotsios A, Kallitsakis I, Bounas A, Dimitroulas T, Garyfallos A, Tektonidou MG, Vosvotekas G, Livieratos A, Petrikkou E, Katsifis G. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study. Qual Life Res 2022;31:1385-1399. [PMID: 34839451 DOI: 10.1007/s11136-021-03044-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/18/2021] [Indexed: 10/19/2022]

Abstract

PURPOSE

To examine the impact of golimumab, on work productivity, activity limitation, and quality of life (QoL) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).

METHODS

This real-world, multicenter, prospective study consecutively enrolled adult consented work-active patients with axSpA or PsA, newly initiated on golimumab as per the approved label. Prior receipt of > 1 prior biologic, or switching from another tumor-necrosis factor inhibitor due to primary non-response or safety reasons was not allowed. The Work Productivity and Activity Impairment-Specific Health Problem and the EuroQol 5-Dimensions (EQ-5D)-5-Level instruments were completed by the patients to assess the impact of golimumab on work productivity and activity impairment, and generic QoL, respectively.

RESULTS

Overall, 121 eligible patients (mean age: 45.4 years; median disease duration: 11.3 months), 51 diagnosed with PsA and 70 with axSpA, were enrolled by 19 rheumatologists. Over a 11.9-month median observation period, < 1% of injections were missed (as collected by patient diaries), and the 12-month golimumab retention rate was 91.7%. At 3, 6, and 12 months post baseline, in the overall population, work productivity loss improved by a median of 31.4%, 44.2%, and 50.0%; activity impairment improved by 40.0%, 40.0%, and 50.0%; and the EQ-5D UK-weighted utility index improved by 0.24, 0.32, and 0.36 points, respectively (p < 0.001 for all). Statistically significant improvements in these measures were also noted in the PsA and axSpA subpopulations.

CONCLUSION

In the routine care in Greece, golimumab displays beneficial effects on work productivity, daily activities, and QoL in work-active patients with axSpA and PsA.

TRIAL REGISTRATION

Trial registration number and date of registration: As per the local regulations the study has been registered at the national registry for non-interventional studies https://www.dilon.sfee.gr/studiesp_d.php?meleti_id=MK8259-6083 .

Collapse

DONMEZ U, OZTURK C, CİNAR E, KOCANAOGULLARİ H, GUCENMEZ S, HEPGULER S. Do physical therapy modalities have additional benefit over exercise therapy in the management of Ankylosing Spondylitis? A randomized controlled trial. EGE TIP DERGISI 2021. [DOI: 10.19161/etd.1037447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open

Alexithymia in ankylosing spondylitis. Turk J Phys Med Rehabil 2021;67:344-350. [PMID: 34870122 PMCID: PMC8606999 DOI: 10.5606/tftrd.2021.6415] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Accepted: 12/14/2020] [Indexed: 12/02/2022] Open

Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials. Rheumatol Int 2021;42:205-213. [PMID: 34773130 DOI: 10.1007/s00296-021-05044-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 10/28/2021] [Indexed: 10/18/2022]

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain and inflammation, and are considered the cornerstone of pharmacological intervention in patients with radiographic axial spondyloarthritis (r-axSpA); however, the long-term use of NSAIDs is debatable due to their restricted therapeutic potential and the risk of side effects and complications. Therefore, reduction in NSAID intake is desirable in r-axSpA patients. Here, we report the long-term NSAID-sparing effect of secukinumab over 4 years in patients with r-axSpA. This post hoc analysis pooled data from 3 secukinumab trials (MEASURE 2-4) for each secukinumab maintenance dose of 150 and 300 mg, regardless of the loading dose regimen being i.v. or s.c. NSAID intake was evaluated prospectively using the Assessment of SpondyloArthritis International Society (ASAS)-NSAID score. Patients with an ASAS-NSAID score > 0 at baseline were analysed. NSAID-sparing endpoints included the mean change in the ASAS-NSAID score, the proportion of patients achieving 50% reduction, and the proportion of patients with an ASAS-NSAID score < 10. Percentages of patients who achieved BASDAI ≤ 2 were also assessed. Overall, 562 patients were included in this pooled analysis (secukinumab: 150 mg, N = 467; 300 mg, N = 95). The mean ASAS-NSAID score decreased with time in both the secukinumab 150 mg and 300 mg dose groups. The proportion of patients who achieved 50% reduction in the ASAS-NSAID score and clinically meaningful reduction of ASAS-NSAID score < 10 increased with time in both dose groups and in both low and high NSAID intake patients. The percentage of patients with a clinically relevant improvement (BASDAI ≤ 2) was consistently higher in patients with an ASAS-NSAID score < 10 than in patients with an ASAS-NSAID score ≥ 10. Secukinumab provided sustained, long-term NSAID-sparing effects in patients with r-axSpA for up to 4 years of treatment, as measured using the ASAS-NSAID score. Trial registered at clinicaltrials.gov: NCT01649375 ( https://clinicaltrials.gov/ct2/show/NCT01649375 ); NCT02008916 ( https://clinicaltrials.gov/ct2/show/NCT02008916 ); NCT02159053 ( https://clinicaltrials.gov/ct2/show/NCT02159053 ).

Collapse

Bodur H, Gül Yurdakul F, Duruöz MT, Çay HF, Uçar Ü, Keskin Y, Sargin B, Gürer G, Yurdakul OV, Çaliş M, Deveci H, Aydin Y, Hizmetli S, Çevik R, Karahan AY, Ataman Ş, Ecesoy H, Günendi Z, Toprak M, Şen N, Altintaş D, Cengiz AK, Çağlayan G, Demir AN, Kaplan H, Ketenci S, Melikoğlu MA, Nayimoğlu M, Nas K, Sarifakioğlu B, Sezer İ. Familial Mediterranean fever: Health-related quality of life and associated variables in a national cohort. Arch Rheumatol 2021;36:159-166. [PMID: 34527919 PMCID: PMC8418764 DOI: 10.46497/archrheumatol.2021.8215] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 07/18/2020] [Indexed: 12/14/2022] Open

Affiliation(s)

Hatice Bodur Department of Physical Medicine and Rehabilitation, Ankara City Hospital, Ankara, Turkey
Fatma Gül Yurdakul Department of Physical Medicine and Rehabilitation, Ankara City Hospital, Ankara, Turkey
Mehmet Tuncay Duruöz Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey
Hasan Fatih Çay Rheumatology, Antalya Training and Research Hospital, Antalya, Turkey
Ülkü Uçar Rheumatology, Antalya Training and Research Hospital, Antalya, Turkey
Yaşar Keskin Department of Physical Medicine and Rehabilitation, Bezmialem Vakıf University Faculty of Medicine, Istanbul, Turkey
Betül Sargin Rheumatology, Adnan Menderes University Faculty of Medicine, Aydın, Turkey
Gülcan Gürer Rheumatology, Adnan Menderes University Faculty of Medicine, Aydın, Turkey
Ozan Volkan Yurdakul Department of Physical Medicine and Rehabilitation, Bezmialem Vakıf University Faculty of Medicine, Istanbul, Turkey
Mustafa Çaliş Department of Physical Medicine and Rehabilitation, Erciyes University Faculty of Medicine, Kayseri, Turkey
Hülya Deveci Department of Physical Medicine and Rehabilitation, Gaziosmanpaşa University Faculty of Medicine, Tokat, Turkey
Yıldıray Aydin Department of Physical Medicine and Rehabilitation, Sakarya University Faculty of Medicine, Sakarya, Turkey
Sami Hizmetli Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey
Remzi Çevik Department of Physical Medicine and Rehabilitation, Dicle University Faculty of Medicine, Diyarbakır, Turkey
Ali Yavuz Karahan Department of Physical Medicine and Rehabilitation, Uşak University Faculty of Medicine, Uşak, Turkey
Şebnem Ataman Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey
Hilal Ecesoy Rheumatology, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey
Zafer Günendi Department of Physical Medicine and Rehabilitation, Gazi University Faculty of Medicine, Ankara, Turkey
Murat Toprak Department of Physical Medicine and Rehabilitation, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey
Nesrin Şen Rheumatology, Kartal Dr. Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey
Duygu Altintaş Rheumatology, Atatürk University Faculty of Medicine, Erzurum, Turkey
Ahmet Kıvanç Cengiz Rheumatology, Sivas Numune Training and Research Hospital, Sivas, Turkey
Gökhan Çağlayan Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey
Ali Nail Demir Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey
Hüseyin Kaplan Department of Physical Medicine and Rehabilitation, Erciyes University Faculty of Medicine, Kayseri, Turkey
Sertaç Ketenci Rheumatology, Giresun University Faculty of Medicine, Giresun, Turkey
Meltem Alkan Melikoğlu Rheumatology, Atatürk University Faculty of Medicine, Erzurum, Turkey
Mehmet Nayimoğlu Department of Physical Medicine and Rehabilitation, Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey
Kemal Nas Department of Physical Medicine and Rehabilitation, Sakarya University Faculty of Medicine, Sakarya, Turkey
Banu Sarifakioğlu Department of Physical Medicine and Rehabilitation, Namık Kemal University Faculty of Medicine, Tekirdağ, Turkey
İlhan Sezer Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey

Collapse

Sieczkowska SM, Smaira FI, Mazzolani BC, Gualano B, Roschel H, Peçanha T. Efficacy of home-based physical activity interventions in patients with autoimmune rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum 2021;51:576-587. [PMID: 33945907 DOI: 10.1016/j.semarthrit.2021.04.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 04/05/2021] [Accepted: 04/06/2021] [Indexed: 01/08/2023]

Affiliation(s)

Sofia Mendes Sieczkowska Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil. Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil Av. Dr. Arnaldo, 455, ZIP code: 01246-903, Sao Paulo-SP, Brazil; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Fabiana Infante Smaira Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil. Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil Av. Dr. Arnaldo, 455, ZIP code: 01246-903, Sao Paulo-SP, Brazil; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Bruna Caruso Mazzolani Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil. Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil Av. Dr. Arnaldo, 455, ZIP code: 01246-903, Sao Paulo-SP, Brazil; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Bruno Gualano Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil. Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil Av. Dr. Arnaldo, 455, ZIP code: 01246-903, Sao Paulo-SP, Brazil; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Hamilton Roschel Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil. Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil Av. Dr. Arnaldo, 455, ZIP code: 01246-903, Sao Paulo-SP, Brazil; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Tiago Peçanha Applied Physiology & Nutrition Research Group, School of Physical Education and Sport, Rheumatology Division, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, SP, Brazil. Laboratory of Assessment and Conditioning in Rhematology, Faculdade de Medicina FMUSP, Disciplina de Reumatologia, Universidade de Sao Paulo, Sao Paulo, SP, Brazil Av. Dr. Arnaldo, 455, ZIP code: 01246-903, Sao Paulo-SP, Brazil; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Collapse

Lim JM, Cho OH. Effects of Home-and-Workplace Combined Exercise for Patients with Ankylosing Spondylitis. Asian Nurs Res (Korean Soc Nurs Sci) 2021;15:181-188. [PMID: 33741506 DOI: 10.1016/j.anr.2021.03.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 02/22/2021] [Accepted: 03/12/2021] [Indexed: 12/17/2022] Open

Gharibdoost F, Salari AH, Salesi M, Ebrahimi Chaharom F, Mottaghi P, Hosseini M, Sahebari M, Nazarinia M, Mirfeizi Z, Shakibi M, Moussavi H, Karimifar M, Mowla K, Karimzadeh H, Anjidani N, Jamshidi A. Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study. Adv Ther 2021;38:1290-1300. [PMID: 33432540 DOI: 10.1007/s12325-020-01611-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Accepted: 12/16/2020] [Indexed: 12/17/2022]

Song Y, Chen H. Predictors of Health-Related Quality of Life in Patients with Ankylosing Spondylitis in Southwest China. Patient Prefer Adherence 2021;15:1887-1894. [PMID: 34483655 PMCID: PMC8409598 DOI: 10.2147/ppa.s324097] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Accepted: 08/22/2021] [Indexed: 02/05/2023] Open

Tahir H, Moorthy A, Chan A. Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives. Open Access Rheumatol 2020;12:277-292. [PMID: 33273869 PMCID: PMC7705257 DOI: 10.2147/oarrr.s265806] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Accepted: 10/06/2020] [Indexed: 12/17/2022] Open

Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, Kim TH, Sengupta R, Šenolt L, Wang Y, Qiu HM, Porter B, Haemmerle S. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5. Chin Med J (Engl) 2020;133:2521-2531. [PMID: 32925287 PMCID: PMC7722578 DOI: 10.1097/cm9.0000000000001099] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Indexed: 02/06/2023] Open

Abstract

BACKGROUND

Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies. Here, we present efficacy and safety results (52-week) of secukinumab in patients with AS from the MEASURE 5 study.

METHODS

MEASURE 5 was a 52-week, Phase III, China-centric study. Eligible patients were randomly assigned (2:1) to receive subcutaneous secukinumab 150 mg or placebo weekly for the first five doses and then once every 4 weeks (q4w). All placebo patients switched to secukinumab 150 mg q4w starting at Week 16. Primary endpoint was Assessments of SpondyloArthritis international Society (ASAS) 20 at Week 16. Randomization was stratified by region (China vs. non-China).

RESULTS

Of 458 patients (secukinumab 150 mg, N = 305; placebo, N = 153) randomized, 327 (71.4%) were from China and 131 (28.6%) were not from China. Of these, 97.7% and 97.4% patients completed Week 16 and 91.1% and 95.3% (placebo-secukinumab) patients completed Week 52 of treatment. The primary endpoint was met; secukinumab significantly improved ASAS20 response at Week 16 vs. placebo (58.4% vs. 36.6%; P < 0.0001); corresponding rate in the Chinese population was 56.0% vs. 38.5% (P < 0.01). All secondary efficacy endpoints significantly improved with secukinumab 150 mg in the overall population at Week 16; responses were maintained with a trend toward increased efficacy from Week 16 to 52. No new or unexpected safety signals were reported up to Week 52.

CONCLUSIONS

Secukinumab 150 mg demonstrated rapid and significant improvement in signs and symptoms of AS. Secukinumab was well tolerated and the safety profile was consistent with previous reports. Efficacy and safety results were comparable between the overall and Chinese populations.

TRIAL REGISTRATION

ClinicalTrials.gov, NCT02896127; https://clinicaltrials.gov/ct2/show/NCT02896127?term=NCT02896127&draw=2&rank=1.

Collapse

Zhao SS, Goodson NJ, Robertson S, Gaffney K. Smoking in spondyloarthritis: unravelling the complexities. Rheumatology (Oxford) 2020;59:1472-1481. [PMID: 32236486 DOI: 10.1093/rheumatology/keaa093] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 12/05/2019] [Accepted: 02/04/2020] [Indexed: 12/17/2022] Open

Sallam RA, Elbahnasawy AS. Health related quality of life (HRQoL) in ankylosing spondylitis patients: Relation to clinical features, disease activity and radiographic damage. THE EGYPTIAN RHEUMATOLOGIST 2020. [DOI: 10.1016/j.ejr.2020.02.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]

Kelly K. Ankylosing spondylitis and undifferentiated spondyloarthritis: The relationship between living with these diseases and psychological well-being. Musculoskeletal Care 2020;19:158-164. [PMID: 32949095 DOI: 10.1002/msc.1513] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Revised: 09/02/2020] [Accepted: 09/06/2020] [Indexed: 12/14/2022]

Garrido-Cumbrera M, Chacón-García J, Navarro-Compán V, Gratacós J, Sanz-Gómez S, Collantes-Estevez E. Does Belonging to a Patient Association Is of Help for Patients with Axial Spondyloarthritis? Results from the Atlas Survey. Curr Rheumatol Rep 2020;22:22. [PMID: 32410101 DOI: 10.1007/s11926-020-00897-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]

How Does Smoking Cessation Affect Disease Activity, Function Loss, and Quality of Life in Smokers With Ankylosing Spondylitis? J Clin Rheumatol 2020;25:288-296. [PMID: 29994796 DOI: 10.1097/rhu.0000000000000851] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]

Abstract

BACKGROUND

Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease that can progressively restrict spinal mobility.

OBJECTIVE

This study aimed to investigate how smoking cessation by AS patients affects disease activity and their psychological state, physical mobility, lung function, and quality of life.

MATERIALS AND METHODS

This was a longitudinal, single-blind, controlled, and observational study on 92 AS patients. Pulmonary function test, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, chest expansion, Short-Form 36, and Ankylosing Spondylitis Quality of Life were evaluated. The patients were divided into smokers (group 1 = 54) and nonsmokers (group 2 = 38). The smokers were divided further into subgroups of those who quit smoking (group 1a = 17) and those who did not (group 1b = 37). Groups 1a and 1b patients were compared in terms of their baseline data and data 6 months after smoking cessation. In addition, group 1a patients' baseline data and data 6 months after smoking cessation were compared statistically.

RESULTS

There was no statistically significant difference between groups 1a and 1b after 6 months in terms of the evaluated parameters, except for BASDAI. Bath Ankylosing Spondylitis Disease Activity Index was significantly lower in group 1a than group 1b (p = 0.02), indicating that. When the baseline data and data after 6 months of group 1a were compared, a significant improvement was found in BASDAI (p = 0.001), Bath Ankylosing Spondylitis Functional Index (p = 0.001), chest expansion (p = 0.001), ankylosing spondylitis quality of life (p = 0.003), and subparameters physical function (p = 0.015), physical role strength (p = 0.05), power/live/vitality (p = 0.025), social functioning (p = 0.039), pain (p = 0.036), and general health perception (p = 0.05) of Short-Form 36, as well as forced expiratory volume in the first second (p = 0.003) and forced vital capacity (p = 0.007).

CONCLUSIONS

We observed significant improvements in disease activity, physical mobility, and quality of life in AS patients who quit smoking.

Collapse

Alkan H, Yildiz N, Ardiç F. The Correlations Between Disease Specific Quality of Life, Short Form-36 and Clinical Variables in Patients With Ankylosing Spondylitis. Arch Rheumatol 2020;35:468-476. [PMID: 33758803 PMCID: PMC7945707 DOI: 10.46497/archrheumatol.2020.7750] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Accepted: 11/10/2019] [Indexed: 11/24/2022] Open

Abstract

Objectives

This study aims to assess the correlations between disease specific quality of life (QoL), general health status and clinical variables in patients with ankylosing spondylitis (AS), and also to determine a cutoff value for the disease specific QoL questionnaire.

Patients and methods

A total of 124 patients (80 males, 44 females; mean age 40.6±11.1 years; range, 20 to 65 years) who fulfilled the modified New York criteria for AS were included in this cross-sectional study. All patients received a comprehensive rheumatologic assessment including disease specific instruments for disease activity, functional status, spinal mobility and QoL. Furthermore, short form-36 (SF-36) was used to determine general health status. Pain levels of the patients were assessed with visual analog scale (VAS). Pearson’s analysis was used to assess correlation among variables, with moderate, strong, or very strong correlations if the value was between 0.40-0.69, 0.70-0.89, and 0.90-0.99, respectively. To determine a cutoff value for the ankylosing spondylitis quality of life (ASQoL) score, the area under the receiver operating characteristic curve (AUC) was computed according to clinical parameters which have the strongest correlations with ASQoL.

Results

The mean ASQoL score was 8.8±4.9. There was a significantly positive correlation between ASQoL and disease activity, functional status, spinal mobility and pain VAS whereas there was a significantly negative correlation between ASQoL and the SF-36 subscale scores except for mental health and emotional role (p<0.001). The strongest positive correlation was found between ASQoL and the Bath Ankylosing Spondylitis Disease Activity Index (r=0.721, p<0.001) whereas the strongest negative correlation was found between ASQoL and the first question of SF-36 (r=-0.844, p<0.001). A cutoff value of eight in ASQoL showed good discriminative properties for impaired QoL where sensitivity and specificity were simultaneously maximized according to disease activity (AUC=0.84 [95% confidence interval (CI): 0.770-0.908, p<0.001]) and the patients’ global health status (AUC=0.85 [95% CI: 0.782-0.923, p<0.001]) in patients with AS.

Conclusion

There was a strong correlation between ASQoL and disease activity as well as the patients’ global health status in patients with AS. A cutoff value of eight in ASQoL could be used with good discriminative properties for impaired QoL in AS.

Collapse

van Bentum RE, Ibáñez Vodnizza SE, Poblete de la Fuente MP, Valenzuela Aldridge F, Navarro-Compán V, Rusman TR, Ter Wee MM, Valenzuela Letelier O, van Weely SFE, van der Horst-Bruinsma IE. The Ankylosing Spondylitis Performance Index: Reliability and Feasibility of an Objective Test for Physical Functioning. J Rheumatol 2020;47:1475-1482. [PMID: 32007935 DOI: 10.3899/jrheum.191063] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/21/2020] [Indexed: 10/25/2022]

Abstract

OBJECTIVE

Physical function in patients with axial spondyloarthritis (axSpA) is currently evaluated through questionnaires. The Ankylosing Spondylitis Performance Index (ASPI) is a performance-based measure for physical functioning, which has been validated in Dutch patients with radiographic (r-) axSpA. The interrater reliability has not yet been determined. To our knowledge, this study is the first to evaluate the validity, reliability, and feasibility of the ASPI in another patient population, including both r- and nonradiographic (nr-) axSpA patients.

METHODS

Patients with axSpA were recruited from rheumatology clinics in Santiago, Chile. Dutch instructions were translated to Spanish by a forward-backward procedure. Study visits were performed at baseline and 1-4 weeks later. Four ASPI observers were involved, measuring the performance times of the 3 ASPI tests. Validity was assessed through a patient questionnaire (numeric rating scale 0-10: ≥ 6 sufficient). For reliability, intraclass correlation coefficients (ICC) were calculated (with 95% CI). Correlations between the ASPI and disease variables were tested with regression analyses.

RESULTS

Sixty-eight patients were included (57% male, 52% r-axSpA). All patients understood the Spanish instructions and considered the ASPI to reach its aim (84%) and representativeness (85%) for physical functioning. The overall interrater (n = 62) and test-retest (n = 39) reliability (ICC) of the 3 tests combined were 0.93 (0.88-0.96) and 0.94 (0.87-0.97), respectively. Eighty-two percent of the patients completed all tests and 94% finished in < 15 min (feasibility).

CONCLUSION

This study demonstrated a high validity and feasibility in an entirely different population, with both r-axSpA and nr-axSpA. The interrater and test-retest reliability was excellent. The ASPI instructions are now available for Spanish-speaking patients.

Collapse

Affiliation(s)

Rianne E van Bentum R.E. van Bentum, MD, T.R. Rusman, MSc, I.E. van der Horst-Bruinsma, MD, PhD, Professor, Department of Rheumatology, Amsterdam University Medical Centre, Vrije Universiteit, Amsterdam, the Netherlands
Sebastian E Ibáñez Vodnizza S.E. Ibáñez Vodnizza, MD, M.P. Poblete de la Fuente, MD, F. Valenzuela Aldridge, MD, O. Valenzuela Letelier, MD, Department of Rheumatology, Clínica Alemana - UDD Medicine Faculty, Santiago, Chile
Maria P Poblete de la Fuente S.E. Ibáñez Vodnizza, MD, M.P. Poblete de la Fuente, MD, F. Valenzuela Aldridge, MD, O. Valenzuela Letelier, MD, Department of Rheumatology, Clínica Alemana - UDD Medicine Faculty, Santiago, Chile
Francisca Valenzuela Aldridge S.E. Ibáñez Vodnizza, MD, M.P. Poblete de la Fuente, MD, F. Valenzuela Aldridge, MD, O. Valenzuela Letelier, MD, Department of Rheumatology, Clínica Alemana - UDD Medicine Faculty, Santiago, Chile
Victoria Navarro-Compán V. Navarro-Compán, MD, PhD, Department of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain
Tamara R Rusman R.E. van Bentum, MD, T.R. Rusman, MSc, I.E. van der Horst-Bruinsma, MD, PhD, Professor, Department of Rheumatology, Amsterdam University Medical Centre, Vrije Universiteit, Amsterdam, the Netherlands
Marieke M Ter Wee M.M. ter Wee, PhD, Department of Rheumatology, Amsterdam University Medical Centre, Vrije Universiteit, and Department of Epidemiology & Biostatistics, Amsterdam Public Health, Amsterdam University Medical Centre, Vrije Universiteit, Amsterdam
Omar Valenzuela Letelier S.E. Ibáñez Vodnizza, MD, M.P. Poblete de la Fuente, MD, F. Valenzuela Aldridge, MD, O. Valenzuela Letelier, MD, Department of Rheumatology, Clínica Alemana - UDD Medicine Faculty, Santiago, Chile
Salima F E van Weely S.F. van Weely, PhD, Department of Orthopedics, Rehabilitation and Physical Therapy, Leiden University Medical Centre, Leiden, the Netherlands
Irene E van der Horst-Bruinsma R.E. van Bentum, MD, T.R. Rusman, MSc, I.E. van der Horst-Bruinsma, MD, PhD, Professor, Department of Rheumatology, Amsterdam University Medical Centre, Vrije Universiteit, Amsterdam, the Netherlands;

Collapse

Lee SH, Park YW, Choe JY, Shin K, Kwon SR, Cha JH, Kim YJ, Lee J, Kim TH. Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea. Int J Rheum Dis 2019;23:342-349. [PMID: 31885217 PMCID: PMC7065053 DOI: 10.1111/1756-185x.13758] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 11/06/2019] [Accepted: 11/07/2019] [Indexed: 12/17/2022]

Relationship Between Health-Related Quality of Life and Patient Acceptable Symptom State With Disease Activity and Functional Status in Patients With Ankylosing Spondylitis in Thailand. J Clin Rheumatol 2019;25:16-23. [PMID: 29509563 DOI: 10.1097/rhu.0000000000000750] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Abstract

OBJECTIVE

This study aimed to identify factors associated with EuroQoL-5 Dimensions, 5 Levels and Patient Acceptable Symptom State (PASS) and health utility (HU) in Thai patients with ankylosing spondylitis (AS).

METHODS

This was a cross-sectional study of consecutive AS patients visiting Siriraj Hospital between May 31, 2012, and March 31, 2016. Demographic data and outcomes related to HU (Thai version of EuroQoL-5 Dimensions, 5 Levels), disease activity (Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score-erythrocyte sedimentation rate or Ankylosing Spondylitis Disease Activity Score-C-reactive protein, number of tender and swollen joints, and enthesitis), and functional status (Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire) were collected. Regression analysis was used to explore factors associated with each EuroQOL-5 Dimensions (EQ-5D) domain, HU, and PASS.

RESULTS

Among 119 AS patients, the mean age was 40.4 years; 61.3% were male. The mean EQ-5D was 0.75. In univariate analysis, lower disease activity and less impaired function were significantly associated with higher HU and not to mild problems in each EQ-5D domain. In multivariate regression analysis, Bath Ankylosing Spondylitis Disease Activity Index, C-reactive protein, and Health Assessment Questionnaire adjusting for age explained 77.4% of the HU variance. Patients answering yes to PASS were significantly older, had higher HU, and lower disease activity compared with those answering no to PASS. Usual activity and pain problems were importantly related to PASS after adjusting for other domains and age.

CONCLUSIONS

Disease activity and functional status in AS patients were significant factors related to HU and PASS. To improve quality of life, treatment goals should be achieving remission, improving function, and controlling pain.

Collapse

Tsang HHL, Chung HY. Pack-year Smoking Associated with Poorer Functional Status, Worsened Spinal Mobility and More Radiological Damages. JOURNAL OF CLINICAL RHEUMATOLOGY AND IMMUNOLOGY 2019. [DOI: 10.1142/s2661341719500032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]

Abstract Introduction: To study the dose-response relationship between smoking and axial Spondyloarthritis (axSpA) disease outcome. Method: One hundred and sixty participants with axSpA were recruited from a single rheumatology center. All of them fulfilled the classification criteria for axSpA by the Assessment of SpondyloArthritis International Society (ASAS). Clinical, demographic and biochemical data was collected. Participants were asked for detailed smoking histories including past and current smoking, smoking duration and quantity. Radiographs of cervical and lumbar spine were performed for modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and modified New York (MNY) criteria for radiological sacroiliitis. Ankylosing Spondylitis Disease Activity Score (ASDAS) was calculated based on C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Univariate and multivariate regression models were performed to determine the associations between pack-year smoking and different disease outcomes. Results: Among the participants, 62 (38.7%) were either current (N [Formula: see text] 39) or former smokers (N [Formula: see text] 23). Ex-smokers quit smoking by 18.8 ± 12.4 years. The mean pack-year for patients who had ever smoked was 19.4 ± 23.1. In univariate analyses, pack-year smoking was associated with BASFI (p <0.001), modified Schober test (p [Formula: see text] 0.01) and mSASSS (p <0.001). Multivariate regression models showed independent dose-response associations between pack-year of smoking and BASFI (SC 0.23; 95% CI 0.01 to 0.06; p [Formula: see text] 0.004), modified Schober test (SC −0.16; 95% CI −0.03 to 0.00; p [Formula: see text] 0.049) and mSASSS (SC 0.22; 95% CI 0.09 to 0.47; p [Formula: see text] 0.01). Conclusion: In Chinese axSpA patients, pack-year smoking was independently associated with poorer functional status, worsened spinal mobility and more radiological damages. Smoking cessation should be encouraged in patients with axSpA. Collapse

Berger S, Andersen R, Dorenberg E, Meyer T, Weiss I, Smaastuen MC, Rosseland LA. Quality of life in patients with vascular malformations outside the central nervous system: Comparison with the general Norwegian population. J Plast Reconstr Aesthet Surg 2019;72:1880-1886. [PMID: 31636028 DOI: 10.1016/j.bjps.2019.09.024] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 08/01/2019] [Accepted: 09/20/2019] [Indexed: 10/25/2022]

Wang HY, Xu X, Li L, Ding CY, Lu J, Zhang YY, Zhang YF, Zhang YL, Sun ZQ. Moxibustion therapy in Chinese patients with ankylosing spondylitis: A randomized controlled pilot trial. Eur J Integr Med 2019;31:100952. [DOI: 10.1016/j.eujim.2019.100952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]

Rosenbaum JT, Pisenti L, Park Y, Howard RA. Insight into the Quality of Life of Patients with Ankylosing Spondylitis: Real-World Data from a US-Based Life Impact Survey. Rheumatol Ther 2019;6:353-367. [PMID: 31111433 PMCID: PMC6702589 DOI: 10.1007/s40744-019-0160-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Indexed: 02/06/2023] Open

Abstract

INTRODUCTION

We aim to assess the real-world, US patient-reported impact of ankylosing spondylitis (AS) on quality of life (QOL) across physical, discomfort, social, and emotional domains.

METHODS

Demographic and QOL data were collected from a random sample of patients associated with the Spondylitis Association of America (SAA) from July to December 2017. QOL measures were based on the Evaluation of Ankylosing Spondylitis Quality of Life (EASi-QoL) questionnaire. The survey evaluated AS impact on the physical domain on the day of survey participation and impact on the discomfort, social, and emotional domains within the week before participation. A 3:1 (male to female) weighting was performed to reflect the reported prevalence of AS in US adults.

RESULTS

Of 820 respondents who completed the survey, 716 self-reported receiving an AS diagnosis from their doctor and were included in this analysis (mean age, 55.5 years; 46.9% male). The mean total EASi-QoL score was 28.9 (weighted); overall, 33.7%, 31.7%, and 34.7% of respondents, respectively, reported a low (EASi-QoL score 0-17), a medium (18-35), and a high (≥ 36) impact of AS on QOL. The physical domain was most impacted; 41.9% of respondents had an EASi-QoL score ≥ 10 (weighted). Women were significantly more likely than men to report a high impact of AS on all QOL domains. Biologic users reported an impact on QOL comparable with the impact on QOL of nonsteroidal anti-inflammatory drug use. AS also impacted lifestyle characteristics, including career choice and sports participation.

CONCLUSION

AS negatively impacted all QOL domains analyzed. The incorporation of subjective measures of disease into disease evaluation should be considered.

FUNDING

Novartis Pharmaceuticals Corporation and UCB, Inc. Plain language summary available for this article.

Collapse

Lu MC, Huang KY, Tung CH, Hsu BB, Wu CH, Koo M, Lai NS. Factors associated with disease-specific quality of life in Taiwanese patients with ankylosing spondylitis: a cross-sectional study. BMJ Open 2019;9:e028966. [PMID: 31182453 PMCID: PMC6561418 DOI: 10.1136/bmjopen-2019-028966] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open

Aykurt Karlıbel İ, Dülger S, Kasapoğlu Aksoy M, Güzelsoy M, Türkoğlu AR, Altan L, Yıldız T. Effect of cigarette smoking on sexual functions, psychological factors, and disease activity in male patients with ankylosing spondylitis. Aging Male 2019;22:109-115. [PMID: 29863428 DOI: 10.1080/13685538.2018.1477935] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open

ÇAPKIN E, KESKİN SB, KARKUCAK M, AYAR A. A prospective clinical investigation of the effects of anti-TNF alpha therapy on exercise capacity in patients with ankylosing spondylitis. Turk J Med Sci 2019;49:27-32. [PMID: 30761840 PMCID: PMC7350836 DOI: 10.3906/sag-1805-291] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open

Law L, Beckman Rehnman J, Deminger A, Klingberg E, Jacobsson LTH, Forsblad-d'Elia H. Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex. Arthritis Res Ther 2018;20:284. [PMID: 30587228 PMCID: PMC6307231 DOI: 10.1186/s13075-018-1784-8] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Accepted: 12/03/2018] [Indexed: 11/30/2022] Open

Abstract

Background

Ankylosing spondylitis (AS) begins early in life and often leads to reduced physical function, but less is known about the impacts it has on health-related quality of life (HRQoL). The aims of this study were to assess HRQoL using the Short Form-36 (SF-36) in a cohort of patients with AS compared with controls and to examine associations between SF-36 scores and spinal radiographic changes, physical function, disease activity and demographic data overall and stratified by sex.

Methods

A cohort of patients with AS from Western Sweden were assessed using the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) with spinal radiographs, clinical examination and questionnaires, including the Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Patient Global (BASG) and SF-36. Each patient’s SF-36 results were compared with those of five age-matched and sex-matched persons (n = 1055) from the SF-36 Swedish normative population database. Associations between SF-36 physical component summary (PCS) and mental component summary (MCS) scores and disease-related and demographic factors were investigated using univariate and multivariable ogistic regression analyses with PCS and MCS below/above their respective median values as dependent variables.

Results

A total of 210 patients, age (median, IQR) 49.0 (21.2) years, symptom duration 24.0 (21.0) years, men 57.6% and HLAB27 87.1% were included. Patients with AS scored significantly lower (p < 0.001) compared to controls in all SF-36 domains and component summaries; PCS 42.4 (14.5) in AS versus 52.4 (11.8) in controls and MCS 47.9 (20.0) in AS versus 54.1 (10.1) in controls. Both men and women scored significantly lower in PCS compared with MCS. Multivariable logistic regression analyses revealed that living without a partner (OR 2.38, 95% CI 1.00–5.67), long symptom duration (year in decade OR 1.66, 95% CI 1.16–2.37), higher BASFI (OR 1.98, 95% CI 1.46–2.70) and ASDAS ≥ 2.1 (OR 3.32, 95% CI 1.45–7.62) were associated with worse PCS, while living without a partner (OR 3.04, 95% CI 1.34–6.91), fatigue (visual analogue scale for global fatigue greater than the median (OR 6.36, 95% CI 3.06–13.19) and ASDAS ≥ 2.1 (OR 2.97, 95% CI 1.41–6.25) with worse MCS. Some differences between sexes were observed in the results.

Conclusions

The patients with AS had significantly lower HRQoL compared with controls. PCS was more affected compared to MCS in both sexes. Both disease-related and demographic factors were associated with HRQoL, partly overlapping for PCS and MCS. Factors associated with HRQoL showed some differences between sexes. By modifying factors, such as ASDAS-CRP and fatigue, HRQoL may potentially be improved.

Trial registration

ClinicalTrials.gov, NCT00858819. Registered on 9 March 2009. Last updated on 28 May 2015.

Electronic supplementary material

The online version of this article (10.1186/s13075-018-1784-8) contains supplementary material, which is available to authorized users.

Collapse

Braun J, Deodhar A, Landewé R, Baraliakos X, Miceli-Richard C, Sieper J, Quebe-Fehling E, Martin R, Porter B, Gandhi KK, van der Heijde D. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open 2018;4:e000749. [PMID: 30564451 PMCID: PMC6269637 DOI: 10.1136/rmdopen-2018-000749] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 10/24/2018] [Accepted: 10/24/2018] [Indexed: 01/02/2023] Open

Akar S, Kaplan YC, Ecemiş S, Keskin-Arslan E, Gercik Ö, Gücenmez S, Solmaz D. The role of smoking in the development and progression of structural damage in axial SpA patients: A systematic review and meta-analysis. Eur J Rheumatol 2018;6:184-192. [PMID: 31657701 DOI: 10.5152/eurjrheum.2019.19073] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Accepted: 05/29/2019] [Indexed: 12/17/2022] Open

Abstract

OBJECTIVE

The objective of this study was to determine whether smoking was associated with the cumulative radiographic spinal damage and radiographic progression in patients with ankylosing spondylitis (AS). Thus, we conducted a systematic review and meta-analysis of the available studies to date.

METHODS

An electronic search was conducted from inception to June 21, 2016, in EMBASE, the MEDLINE/PubMed Cochrane Central Register of Controlled Trials databases. Cross-sectional and longitudinal cohort studies investigating the association between smoking and cumulative spinal structural damage or radiographic progression were included. The outcome of interest was the presence of syndesmophytes in cross-sectional studies and radiographic progression in longitudinal studies. The quality assessment was done using the Agency for Healthcare Research and Quality checklist. The authors of potentially relevant studies were contacted regarding the unpublished data. Data from eligible cross-sectional studies were extracted and arranged in a 2x2 table. The odds ratios (ORs) and 95% confidence intervals (CIs) for the dichotomous outcome of interest were computed.

RESULTS

The combined data of eight eligible cross-sectional studies for the assessment of association between smoking and cumulative spinal structural damage suggested a significant association (OR, 2.02; 95% CI, 1.51-2.70). No significant heterogeneity was detected between studies (I²=23.0%, p=0.25). The heterogeneity of the longitudinal study data did not permit us to undertake a meta-analysis. Hence, a qualitative review was performed.

CONCLUSION

The results of our meta-analysis show that smoking is associated with increased cumulative spinal structural damage in patients with AS. Therefore, rheumatologists should encourage patients with AS to quit smoking.

Collapse

Gunay SM, Keser I, Bicer ZT. The effects of balance and postural stability exercises on spa based rehabilitation programme in patients with ankylosing spondylitis. J Back Musculoskelet Rehabil 2018;31:337-346. [PMID: 28946534 DOI: 10.3233/bmr-169755] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]

Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Vis M. Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis. J Rheumatol 2018;45:1526-1531. [PMID: 29961685 DOI: 10.3899/jrheum.171406] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/24/2018] [Indexed: 11/22/2022]

Affiliation(s)

Kim Wervers From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Jolanda J Luime From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Ilja Tchetverikov From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Andreas H Gerards From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Marc R Kok From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Cathelijne W Y Appels From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Wiebo L van der Graaff From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Johannes H L M van Groenendael From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Lindy-Anne Korswagen From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Josien J Veris-van Dieren From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Johanna M W Hazes From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands.,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center
Marijn Vis From the Dutch south-west Early Psoriatic Arthritis cohort (DEPAR): Department of Rheumatology, Erasmus University Medical Center, and Maasstad Hospital, and Sint Franciscus Gasthuis, Rotterdam; Albert Schweitzer Hospital, Dordrecht; Vlietland Hospital, Schiedam; Amphia Hospital, Breda; Rivas Hospital, Gorinchem; Reumazorg Zuid West Nederland, Roosendaal, the Netherlands. .,K. Wervers, PhD Student, Department of Rheumatology, Erasmus University Medical Center; J.J. Luime, PhD, Department of Rheumatology, Erasmus University Medical Center; I. Tchetverikov, MD, PhD, Department of Rheumatology, Albert Schweitzer Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.H. Gerards, MD, Department of Rheumatology, Vlietland Hospital; C.W. Appels, MD, Department of Rheumatology, Amphia Hospital; W.L. van der Graaff, MD, PhD, Department of Rheumatology, Rivas Hospital; J.H. van Groenendael, MD, Reumazorg Zuid West Nederland; L.A. Korswagen, MD, Department of Rheumatology, Sint Franciscus Gasthuis; J.J. Veris-van Dieren, MD, Reumazorg Zuid West Nederland; J.M. Hazes, MD, PhD, Department of Rheumatology, Erasmus University Medical Center; M. Vis, MD, PhD, Department of Rheumatology, Erasmus University Medical Center.

Collapse

Association of neuropathic-like pain characteristics with clinical and radiographic features in patients with ankylosing spondylitis. Clin Rheumatol 2018;37:3077-3086. [PMID: 29713968 DOI: 10.1007/s10067-018-4125-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 04/12/2018] [Accepted: 04/24/2018] [Indexed: 02/07/2023]

Turkish Version of Evaluation of Ankylosing Spondylitis Quality of Life Questionnaire in Patients With Ankylosing Spondylitis: A Validation and Reliability Study. Arch Rheumatol 2018;33:443-454. [PMID: 30874240 DOI: 10.5606/archrheumatol.2018.6614] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Accepted: 01/24/2018] [Indexed: 11/21/2022] Open

Abstract

Objectives

This study aims to translate the Evaluation of Ankylosing Spondylitis Quality of Life (EASi-QoL) into the Turkish language and test its validity and reliability.

Patients and methods

A total of 100 AS patients (74 males; 26 females; mean age 38.2±9.9 years; range 21 to 63 years) were included. The mean disease duration was 115.9±91.6 months. EASi-QoL was translated from English into Turkish, and synthesis, back translation, revision, and pretest stages were performed. All patients were asked to complete the Turkish version of EASi-QoL. The internal consistency of EASi-QoL was determined with Cronbach's alpha coefficient, and test-retest reliability was assessed by calculating the intra-class correlation coefficient. Confirmatory and explanatory factor analyses were performed to assess structural validity. Construct validity was also investigated by comparing the results of EASi-QoL with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Ankylosing Spondylitis Disease Activity Score, Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), and AS-specific QoL scale.

Results

Cronbach's alpha coefficient was 0.910 in the physical function category, 0.893 in the disease activity category, 0.935 in the emotional well- being category, and 0.930 in the social contribution category (α>0.7). Factor loadings of all items in EASi-QoL were higher than 0.7, indicating the high reliability of the questionnaire. There was also a strong positive correlation between all subcategories of EASi-QoL (physical function, disease activity, emotional well-being and social participation) and AS-specific QoL scale, BASDAI, Bath BASFI, patient's global assessment and pain severity. MASES and BASMI showed a moderate correlation with emotional well-being and social participation categories of EASi-QoL.

Conclusion

Turkish version of EASi-QoL is a reliable and valid scale that can be used in clinical practice to evaluate QoL in detail in patients with AS.

Collapse

Gürer G, Taşçı Bozbaş G, İyiyapıcı Ünübol A, Tuncer T, Bütün B. Which Factors Affect the Functional Situation and Quality of Life in Patients with Ankylosing Spondylitis? ANKARA MEDICAL JOURNAL 2017. [DOI: 10.17098/amj.364155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open

The Effectiveness of Structured Group Education on Ankylosing Spondylitis Patients. J Clin Rheumatol 2017;23:138-143. [PMID: 28248799 DOI: 10.1097/rhu.0000000000000499] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Huang JC, Qian BP, Qiu Y, Wang B, Yu Y, Zhu ZZ, Hu J, Qu Z. Quality of life and correlation with clinical and radiographic variables in patients with ankylosing spondylitis: a retrospective case series study. BMC Musculoskelet Disord 2017;18:352. [PMID: 28810915 PMCID: PMC5558739 DOI: 10.1186/s12891-017-1711-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 08/08/2017] [Indexed: 12/29/2022] Open

Abstract

Background

Previously, many studies have evaluated quality of life (QoL) in patients with ankylosing spondylitis (AS), however, none of them specifically investigated the correlation between pain-related disability measured by Oswestry Disability Index (ODI) and QoL in AS patients. In addition, the correlation between global kyphosis (GK) in lateral plain radiographs and QoL in AS patients remains unclear up to now. Therefore, this study aimed to evaluate QoL and correlation with clinical and radiographic variables in AS patients, especially to figure out the relationship about the pain-specific disability measured by ODI, GK and QoL.

Methods

From January 2008 to November 2015, two hundred and forty-five consecutive patients with an average age of 36.2 ± 10.9 years (range, 17–66 years) satisfying the Modified New York Criteria for AS from a single institution were enrolled. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI) and Bath Ankylosing Spondylitis Global score (BAS-G) were applied to assess the disease activity, functional status, spinal mobility and overall feeling of AS patients, respectively. ODI was recorded to evaluate low back pain-related disability. QoL was evaluated by the Short Form-36 (SF-36). According to global kyphosis (GK) measured on standing lateral full-spine radiographs, the patients were divided into two groups: mild kyphotic group (GK < 70°,n = 176) and severe kyphotic group (GK ≥ 70°,n = 69).

Results

The scores of BASDAI, BASFI, BASMI and ODI had significant negative correlations with all SF-36 subscale scores (P < 0.01). BASFI and BASMI scores of severe kyphotic group were much higher than those of mild kyphotic group, respectively (P = 0.005 and P = 0.001, respectively) and the score of physical function (PF) subscale in severe kyphotic group was significantly higher than that in mild kyphotic group (P = 0.046) as well. Notably, the scores of ODI, BASFI and BASMI were the major predictors of PF subscale score of SF-36.

Conclusions

Poor QoL is significantly correlated with high disease activity, poor functional status and decreased spinal mobility in AS. GK is significantly associated with functional status, spinal mobility and QoL in AS patients. ODI, BASFI and BASMI are the major predictors of PF subscale of SF-36.

Collapse

Jones GT, Ratz T, Dean LE, Macfarlane GJ, Atzeni F. Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. Arthritis Care Res (Hoboken) 2017;69:1407-1413. [DOI: 10.1002/acr.23157] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Revised: 09/30/2016] [Accepted: 11/22/2016] [Indexed: 12/17/2022]

Sagittal Vertical Axias, Spinosacral Angle, Spinopelvic Angle, and T1 Pelvic Angle: Which Parameters May Effectively Predict the Quality of Life in Ankylosing Spondylitis Patients With Thoracolumbar Kyphosis? Clin Spine Surg 2017;30:E871-E876. [PMID: 27841801 DOI: 10.1097/bsd.0000000000000463] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Abstract

STUDY DESIGN

This is a retrospective study.

OBJECTIVE

To identify the relationship between global sagittal alignment and health-related quality of life (HRQoL) in ankylosing spondylitis (AS) patients with thoracolumbar kyphosis.

SUMMARY OF BACKGROUND DATA

Little data are available on correlation between global sagittal alignment and HRQoL in AS.

MATERIALS AND METHODS

A total of 107 AS patients were included in this study. The radiographic parameters were measured on lateral radiographs of the whole spine, including sagittal vertical axias (SVA), spinosacral angle (SSA), spinopelvic angle (SPA), and T1 pelvic angle (TPA). HRQoL was assessed using the oswestry disability index questionnaire, the bath ankylosing spondylitis disease activity index, the bath ankylosing spondylitis functional index, and short form-36 questionnaire. The patients were divided into 2 groups: group A (n=76, global kyphosis≤70 degrees), group B (n=31, global kyphosis>70 degrees). Statistical analysis was performed to identify significant differences between these 2 groups. In addition, correlation analysis and multiple regression analysis between radiologic parameters and clinical questionnaires were conducted.

RESULTS

With respect to SVA, SSA, SPA, TPA, and HRQoL scores, significant differences were observed between 2 groups (P<0.05). Also, SVA, SSA, SPA, and TPA were significantly related to HRQoL. Multiple regression analysis revealed that SVA, SSA, SPA, and TPA were significant parameters in the prediction of HRQoL in AS patients with thoracolumbar kyphosis. Of note, HRQoL related much more to SSA and SPA than SVA and TPA.

CONCLUSIONS

AS patients with moderate and severe deformity were demonstrated to be significantly different in terms of SVA, SSA, SPA, TPA, and HRQoL. Moreover, SVA, SSA, SPA, and TPA correlated with HRQoL significantly. In particular, SSA and SPA could better predict HRQoL than SVA and TPA in AS patients with thoracolumbar kyphosis.

Collapse